Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by XTX Topco Ltd

XTX Topco Ltd decreased its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 62.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,252 shares of the company’s stock after selling 15,247 shares during the period. XTX Topco Ltd’s holdings in Harmony Biosciences were worth $292,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. American Century Companies Inc. increased its holdings in shares of Harmony Biosciences by 16.5% during the 2nd quarter. American Century Companies Inc. now owns 1,501,420 shares of the company’s stock worth $47,445,000 after buying an additional 212,633 shares during the last quarter. LSV Asset Management grew its position in Harmony Biosciences by 24.6% during the second quarter. LSV Asset Management now owns 1,488,502 shares of the company’s stock valued at $47,037,000 after acquiring an additional 293,541 shares during the period. Geode Capital Management LLC increased its position in Harmony Biosciences by 9.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,054,348 shares of the company’s stock worth $33,321,000 after purchasing an additional 88,598 shares in the last quarter. Boston Partners purchased a new stake in Harmony Biosciences during the second quarter worth approximately $19,398,000. Finally, New Vernon Capital Holdings II LLC increased its position in shares of Harmony Biosciences by 3,219.0% in the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock worth $16,211,000 after acquiring an additional 473,708 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HRMY. Oppenheimer restated an “outperform” rating and set a $62.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of Harmony Biosciences in a research report on Monday, November 24th. Deutsche Bank Aktiengesellschaft lowered their target price on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. Finally, HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.63.

Harmony Biosciences Price Performance

HRMY stock opened at $39.83 on Monday. The stock’s 50 day moving average is $30.78 and its two-hundred day moving average is $33.09. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $40.93. The company has a market capitalization of $2.29 billion, a PE ratio of 12.53, a P/E/G ratio of 0.52 and a beta of 0.80. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The company had revenue of $239.46 million for the quarter, compared to analyst estimates of $222.68 million. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.